共 50 条
- [42] Letter by Morel et al Regarding Article, "Ischemic Postconditioning During Primary Percutaneous Coronary Intervention: The Effects of Postconditioning on Myocardial Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction (POST) Randomized Trial" CIRCULATION, 2014, 130 (06) : E53 - E53
- [43] Letter by Ma et al Regarding Article, "Ischemic Postconditioning During Primary Percutaneous Coronary Intervention: The Effects of Postconditioning on Myocardial Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction (POST) Randomized Trial" CIRCULATION, 2014, 130 (06) : E52 - E52
- [45] Letter by Packard Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial" CIRCULATION, 2020, 142 (20) : E333 - E334
- [47] Letter by Al-Atassi et al Regarding Article, "Cost-Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Bypass Surgery for Patients With 3-Vessel or Left Main Coronary Artery Disease: Final Results From the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial" CIRCULATION, 2015, 132 (01) : e10 - e10
- [50] Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis from the Randomized TROPICAL-ACS Trial NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 : S13 - S14